搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
8 小时
Lonza to produce Casgevy for Vertex
Swiss contract development and manufacturing organization (CDMO) Lonza (VTX: LONN) has signed a long-term commercial supply ...
FiercePharma
1 天
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Pharmaceutical Technology
3 小时
Epigenetic drugs show 375% increase in Series A venture financing in 2024
The epigenetic drugs space has witnessed a two-fold increase in Series A venture funding, with total deal value increasing to ...
1 天
Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene ...
Basel, Switzerland, 24 September 2024 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today the signature of a long-term commercial supply ...
nai500
12 天
回调即是买入机会,这只下跌62%的基因编辑股建议关注
在过去三年中,CRISPR Therapeutics ...
12 天
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...
16 天
罕见遗传病新希望——基因治疗药物,让血友病、SMA等不再“无药可 ...
对于传统疗法束手无策的罕见遗传疾病,基因治疗同样也开辟了新的治疗路径。通过基因替代、基因编辑及基因修饰等创新策略,促使人体基因正常表达,以达到治疗效果。基因治疗药物为众多曾被传统疗法束缚的罕见遗传病治疗领域带来了前所未有的希望。
BioSpace
14 天
Vertex, CRISPR’s Casgevy Highlights Complex Path to Gene Therapy Profitability
No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...
3 天
The Best Biotech Stock to Invest $1,000 in Right Now
The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group ...
Nature
8 天
Doctors cured her sickle-cell disease. So why is she still in pain?
Gene and cell therapies bring fresh hope to people with genetic disorders, but recovery can be complex and long-term support ...
FiercePharma
1 天
Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat
After bluebird bio acknowledged troubles keeping its business operational, the gene therapy biotech is launching a ...
13 天
1 Biotech Stock Down 62% to Buy and Hold
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈